Indaptus halts Decoy20 enrollment, pivots to strategic review after Q2 2026
Indaptus Therapeutics reported no active clinical programs and a new sleep-related research collaboration as it evaluates strategic alternatives following a $12.0 million private placement.
Indaptus Therapeutics reported second quarter and six-month 2026 financial results on August 13, 2026, alongside a corporate update describing a shift away from active clinical development. The Company has discontinued further enrollment in its combination study, has no participants remaining in any ongoing Decoy20 clinical study and currently has no active clinical development programs.1 Indaptus said it has reduced activities related to further development of Decoy20 while it evaluates strategic alternatives for its Decoy20 program and broader operations, including research collaborations, investments in or acquisitions of operating businesses and other potential growth opportunities.1
As part of that pivot, during the second quarter the company began a research collaboration in neurological disorders and sleep as an extension of its immunotherapy research.1 The Company seeks to better understand the relationship among sleep, physical recovery, neurological function and immune status, which could potentially support future immunotherapy evaluation, patient recovery monitoring and biomarker research.1
On financing, on June 17, 2026, the Company issued and sold 20,000,000 shares of common stock at $0.60 per share for aggregate gross proceeds of approximately $12.0 million before offering expenses, with the transaction closing the same day.1
On liquidity, as of June 30, 2026, the Company had approximately $7.6 million in cash and cash equivalents and $4.0 million in short-term investments.1 Based on current operating plans and available financial resources, management said the Company's liquidity position had been strengthened compared to the first quarter end.1 The Company said it may seek additional public or private equity or debt financing to support its operations and strategic objectives.1
Separately, at its August 10, 2026 annual meeting, shareholders approved the Indaptus Therapeutics, Inc. 2026 Equity Incentive Plan, and elected David Natan, Tim Ruan and Dr. Johnny Fox Arrowsmith as Class II directors.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.